Evidence map›Paper›PMID 33432228›Full record

ArticleNature immunology2021

Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation.

Martín A Rivas, Cem Meydan, Christopher R Chin, Matt F Challman, Daleum Kim, Bhavneet Bhinder, Andreas Kloetgen, Aaron D Viny, Matt R Teater, Dylan R McNally and 11 more

Open access · greenAbstract readComparative Study
In one paragraph

Article in Nature immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. A STAG2-PAXIP1/PAGR1 axis suppresses lung tumorigenesis.The Journal of experimental medicine · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Recurrent Germline Variant inInternational journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 2 countries.

Martín A RivasDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-9603-6897
Cem MeydanDepartment of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.
Christopher R ChinDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-2140-3197
Matt F ChallmanDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Daleum KimDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Bhavneet BhinderCaryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
Andreas KloetgenDepartment of Pathology, New York University School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0003-0991-4442
Aaron D VinyHuman Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-7039-0110
Matt R TeaterDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Dylan R McNallyDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Ashley S DoaneDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-1489-1786
Wendy BéguelinDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-4894-9229
María Teresa Calvo FernándezDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Hao ShenDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Xiang WangDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Ross L LevineHuman Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-7884-1905
Zhengming ChenDivision of Biostatistics and Epidemiology, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
Aristotelis TsirigosDepartment of Pathology, New York University School of Medicine, New York, NY, USA.
Olivier ElementoDepartment of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.
Christopher E MasonDepartment of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-1850-1642
Ari M MelnickDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA. amm2014@med.cornell.edu.ORCID http://orcid.org/0000-0002-8074-2287
Cornell University · USMemorial Sloan Kettering Cancer Center · USNew York University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Disparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2M
Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 1985 to 2026
$83.1M
The impact of changes in chromatin architecture on cancer phenotypes and tumor progressionP01CA229086 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Jane Amanda Skok · 2019 to 2026
$17.0M
TRANS-NETWORK PROJECTSU54CA143869 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MARKO, JOHN F · 2009 to 2013
$12.8M
Synergistic role of signaling and epigenetics in leukemic transformationR35CA197594 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Ross L Levine · 2017 to 2026
$11.4M
Project 3: Targeting PRMT5 in Mantle Cell LymphomaP01CA214274 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI BAIOCCHI, ROBERT ALAN · 2018 to 2022
$8.9M
Targeting Epigenetic Circuits in B-Cell LymphomasR35CA220499 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MELNICK, ARI M. · 2018 to 2024
$7.2M
Defining the role of the RNA modification N6-methyladenosine in the hepatitis C virus lifecycleR01AI125416 · NIAID · DUKE UNIVERSITY · PI Stacy Michelle Horner · 2016 to 2026
$5.5M
Targeting Epigenetic Heterogeneity in Pediatric T cell leukemia: Epi-Clones as Drivers of ChemoresistanceR01CA252239 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aristotelis Tsirigos · 2021 to 2026
$3.7M
Clinical and Molecular Heterogeneity in the Myelodysplastic SyndromesR01CA249054 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MASON, CHRISTOPHER EDWARD, PARK, CHRISTOPHER Y · 2020 to 2024
$3.5M
Metagenomic profiling of urinary cell-free DNA to monitor urinary tract infection after kidney transplantationR01AI151059 · NIAID · CORNELL UNIVERSITY · PI DADHANIA, DARSHANA, DE VLAMINCK, IWIJN · 2020 to 2024
$3.4M
NCATS NIH HHS UL1 TR002384NCI NIH HHS K08 CA215317NCI NIH HHS P01 CA214274NCI NIH HHS P01 CA229086NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016087NCI NIH HHS R01 CA194547NCI NIH HHS R01 CA216421NCI NIH HHS R01 CA228528NCI NIH HHS R01 CA249054NCI NIH HHS R01 CA252239NCI NIH HHS R35 CA197594NCI NIH HHS R35 CA220499NCI NIH HHS U54 CA143869NHLBI NIH HHS T32 HL135465NIAID NIH HHS R01 AI125416NIAID NIH HHS R01 AI151059NIAID NIH HHS R21 AI129851
6 · The paper itself

Abstract

During the germinal center (GC) reaction, B cells undergo extensive redistribution of cohesin complex and three-dimensional reorganization of their genomes. Yet, the significance of cohesin and architectural programming in the humoral immune response is unknown. Herein we report that homozygous deletion of Smc3, encoding the cohesin ATPase subunit, abrogated GC formation, while, in marked contrast, Smc3 haploinsufficiency resulted in GC hyperplasia, skewing of GC polarity and impaired plasma cell (PC) differentiation. Genome-wide chromosomal conformation and transcriptional profiling revealed defects in GC B cell terminal differentiation programs controlled by the lymphoma epigenetic tumor suppressors Tet2 and Kmt2d and failure of Smc3-haploinsufficient GC B cells to switch from B cell- to PC-defining transcription factors. Smc3 haploinsufficiency preferentially impaired the connectivity of enhancer elements controlling various lymphoma tumor suppressor genes, and, accordingly, Smc3 haploinsufficiency accelerated lymphomagenesis in mice with constitutive Bcl6 expression. Collectively, our data indicate a dose-dependent function for cohesin in humoral immunity to facilitate the B cell to PC phenotypic switch while restricting malignant transformation.

Indexed as

Gene DosageImmunity, HumoralAnimalsB-LymphocytesCell Cycle ProteinsCell DifferentiationCell ProliferationCells, CulturedCell Transformation, NeoplasticChondroitin Sulfate ProteoglycansChromosomal Proteins, Non-HistoneCohesinsDioxygenasesDNA-Binding ProteinsGene DeletionGene Expression Regulation, NeoplasticCell Cycle ProteinsChondroitin Sulfate ProteoglycansChromosomal Proteins, Non-HistoneCohesinsDioxygenasesDNA-Binding ProteinsHistone-Lysine N-MethyltransferaseKmt2d protein, mouseMyeloid-Lymphoid Leukemia ProteinProto-Oncogene ProteinsSMC3 protein, humanSMC3 protein, mouseTet2 protein, mouse

Identifiers

PMID33432228
PMCPMC7855695
OpenAlexW3120574697

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.